PharmaMar will present in the IASLC congress results of lurbinectedin on Small-Cell Lung Cancer

On August 13, 2018 PharmaMar (MSE:PHM) reported that The International Association for the Study of Lung Cancer (IASLC) announced on Friday August 10th the titles for the presentations at the 19th World Conference on Lung cancer which will take place September 23-26 in Toronto, Canada (Press release, PharmaMar, AUG 13, 2018, View Source [SID1234528928]). PharmaMar will present a poster titled "Overall survival with lurbinectedin plus doxorubicin in relapsed SCLC. Results from an expansion cohort of a phase Ib trial"

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!